ACLS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wu, T.-J.
Right arrow Articles by Kao, P. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wu, T.-J.
Right arrow Articles by Kao, P. C.
Annals of Clinical & Laboratory Science 33:423-428 (2003)
© 2003 Association of Clinical Scientists

Thyroxine Effects on Serum Insulin-like Growth Factor I Levels, Anthropometric Measures, and Body Composition in Patients After Thyroidectomy

Ta-Jen Wu1, Shih-Ming Huang2, Robert L. Taylor3 and Pai C. Kao3
1 Department of Internal Medicine, National Cheng Kung University Hospital
2 Department of Surgery, Tzu Chi Buddhist General Hospital, Taiwan, Republic of China
3 Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.

Address correspondence to Pai C. Kao, Ph.D., Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA; tel 507 284 2691; fax 507 284 5036; e-mail kao.pai{at}mayo.edu

Thyroxine is an important hormone related to growth. To study the effects of thyroxine on serum levels of insulin-like growth factor I (IGF-I), anthropometric measures, and body composition, we studied 28 patients who were receiving thyroxine therapy after thyroidectomy for well-differentiated thyroid cancer. Serum IGF-I levels decreased from 38.3 ± 19.0 ng/ml (mean ± SD) to 26.8 ± 12.8 ng/ml (p <0.001) after withdrawal of thyroxine and increased to 43.8 ± 20.2 ng/ml (p <0.001) after thyroxine was resumed. The serum levels of TSH, T3, and thyroxine changed accordingly after withdrawal and resumption of thyroxine therapy. Skinfold thickness increased from 21.8 ± 6.5 mm to 23.7 ± 6.4 mm (p <0.001) after withdrawal of thyroxine and decreased to 21.5 ± 6.9 mm after resumption of thyroxine. Similar changes occurred in the circumferences of the waist and hip (p <0.01), but no significant change occurred in arm muscle circumference (18.7 ± 2.3 cm vs 18.7 ± 2.3 cm vs 19.0 ± 2.4 cm). Body composition analysis by bioelectrical impedance showed no significant changes in the percentages of body fat and lean mass. In conclusion, withdrawal of thyroxine from patients with thyroid cancer was associated with an immediate decrease in serum IGF-I levels. However, lean mass did not respond to the changes in serum IGF-I levels.

Keywords: insulin-like growth factor I, body composition, thyroid, thyroxine






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the Association of Clinical Scientists.